sábado, 25 de noviembre de 2023

Farmacias de..."Black Fryday"


El ‘Viernes Negro’, más conocido como ‘Black Friday’  entraró en numerosas farmacias españolas que aprovechan esta iniciativa, nacida en EE.UU., para potenciar las ventas de cara al inicio de la campaña de Navidad, a través de suculentos descuentos. Las boticas, si es cierto, deben ceñirse a ofrecer promociones en productos de parafarmacia ya que los medicamentos no pueden optar a descuentos.

viernes, 24 de noviembre de 2023

Cinema Paradiso: How To Help Cure a Cold / Walt Disney

Ahora que Disney cumplee 100 años 

vaya, desde PHARMACOSERIAS,     

nuestro homenaje

"How to cure a Cold"

is a 1951 American animated educational short film which shows how to avoid catching a cold. 

An updated version of this short was released in 1986 with live-action segments.

"How to Catch a Cold" is an animated short produced by Disney in 1951, sponsored by Kleenex, the tissue company. 

I t follows an unnamed man, stricken with a cold, who is given advice by a man who calls himself Common Sense. 

He tells the man what to do to avoid catching future colds, how to look after oneself while sick with a cold, and how to avoid getting other people sick. It has a bit of outdated information, such as the old idea that going out in the rain makes you susceptible to illness, so decades later, a live-action version was made staring Goofy educating a little boy named Jeff who also had a cold, that used more scientifically accurate information.


jueves, 23 de noviembre de 2023

Ahora Pharma también es "WOKE": WOKE Pharmaceuticals


Woke Pharmaceuticals Pty Ltd is an Australian-based company focused on the development and commercialisation of novel psychedelic therapies for the treatment of mental health disorders

About 20% of Australians struggle with a mental illness every year, ranging from depression and anxiety to substance or alcohol abuse. The potential hardship and isolation posed by COVID-19 risks leaving more people vulnerable.

While there is a range of pharmaceutical and psychological treatments for mental illness, these may not be effective in some people, or at least they may still leave people with residual symptoms. Additionally, there are usually side effects which commonly occur from these drug therapies.

Given the scale of mental illness in society, innovative new treatment approaches are urgently needed. One of these new approaches is the medicinal use of previously prohibited psychedelic compounds such as magic mushrooms. There have been several successful clinical studies across the world that have shown the potential benefit of psychedelics for treatment of psychiatric disorders. 


Todo sobre  psilocybin en PHARMACOSERÍAS

Woke Pharmaceuticals' lead candidates are based on synthetic psilocybin for the treatment of depression. Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi. The safety and efficacy of psilocybin has been demonstrated in multiple studies.

Mission Statement 

Woke Pharmaceuticals is dedicated to developing novel psychedelic therapies as registered medical treatments for mental health disorders and other neurological diseases, as well as supporting psychological wellbeing. We aim to achieve this through the development of novel formulations, rigorous research and clinical trials, and partnerships with world-class researchers, institutions, organisations, and corporations.


Para el 2021, "woke" se había usado casi exclusivamente como un concepto peyorativo, y los usos más destacados de la palabra tienen lugar en un contexto despectivo.​ Aunque en español no tiene una traducción asentada y generalmente se usa el término inglés crudo, destacada en cursiva o entrecomillada al ser un extranjerismo, en la jerga coloquial de España se llama despiertismo a este movimiento y despiertos o despiertitos a los que lo siguen, el primero como término neutro y el segundo despectivo. Una traducción propuesta por la RAE es concienciado.

miércoles, 22 de noviembre de 2023

ROCHE Ocrevus: 10 year data shows cuts disability progresion...


Roche's  multiple sclerosis (MS) drug Ocrevus showed that after 10 years of treatment 77% of patients with relapsing MS were free from disability progression and 92% continued to walk without help.

The Swiss pharma giant reported 10 years of follow-up data from its three phase 3 trials of Ocrevus (ocrelizumab), noting that the drug is the first and only disease-modifying treatment (DMT) in MS to benefit both people with RMS and primary progressive MS (PPMS).

After 10 years of treatment with Ocrevus 77% of people were free from disability progression based on 48-week confirmed disability progression events, while 92% of the patients were still walking unassisted.

In addition, in patients with PPMS, 36% were free from disability progression and 80% of patients treated continuously with the medicine over 10 years were still able to walk, according to the company.

Roche noted that new safety data from 6,155 patients with exposure to Ocrevus across 12 trials support the drug's favourable benefit-risk profile, which has remained consistent over 10 years.

The company added that safety data from 3,253 cumulative pregnancies in women with MS did not indicate an increased risk of adverse pregnancy or infant outcomes in women with MS who were treated with the drug.

"With more than 300,000 people treated globally and 30 ongoing trials, we continue to accrue robust evidence for how OCREVUS may benefit many underrepresented groups including pregnant women and people of Black or Hispanic heritage," said Levi Garraway, head of Global Product Development and chief medical officer, Roche.

Roche also shared one-year efficacy and safety data from a phase 4 study called CHIMES, which the company said is the first-ever trial focused exclusively on broadening understanding of MS disease biology among Black and Hispanic / Latinx people with MS.

The data showed that Ocrevus controlled disease activity and disability progression in these populations, demonstrating a safety and efficacy profile consistent with other trials of the drug.